Anitocabtagene Autoleucel trial enters registry as Phase 3 multiple myeloma study takes shape
A new Phase 3 ClinicalTrials.gov registry observation shows a randomized study of anitocabtagene autoleucel versus standard care in newly diagnosed multiple myeloma, with no results posted yet.
A new ClinicalTrials.gov registry observation puts anitocabtagene autoleucel in focus for people with newly diagnosed multiple myeloma. The study is listed as PHASE3 and NOT_YET_RECRUITING, so the current story is about the trial’s setup, not about results.
Published 2026-11-16T00:00:00+00:00, the study is titled "To Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma". It is sponsored by Kite, A Gilead Company and is designed as a RANDOMIZED comparison, which means participants are assigned to study arms by chance.
"This record describes a study and its registry status; study outcomes require posted results." source: ctgov_v2
What the trial is comparing
The record shows two arms: Arm A: Standard of Care Therapy (SOCT) and Arm B: Anitocabtagene Autoleucel. The comparison is direct, which makes the registry entry easy to read for anyone trying to understand whether a cell-based approach may be tested against current care.
Several treatments appear across both arms, including Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone. The experimental arm also includes Fludarabine and Cyclophosphamide, while Melphalan is listed only for Arm A: Standard of Care Therapy (SOCT).
Why the endpoints matter
The first main readout is Minimal Residual Disease (MRD)-Negative Complete Response (CR) or Stringent CR (sCR) Rate at 12 Months, with the assessment window listed as Up to 12 months. In plain terms, that looks for very deep responses to treatment, not just symptom control.
A second endpoint is Progression-Free Survival (PFS) for up to 15 years. That measures the time from randomization until the disease gets worse or death occurs, so it gives a longer view of how durable the treatment strategy may be.
"PFS is defined as the time from randomization to the first documented disease progression per International Myeloma Working Group (IMWG) criteria as determined by the Independent Review Committee (IRC), or death due to any cause, whichever occurs first." source: ctgov_v2
How this fits the wider gene and cell therapy picture
The trial sits inside the active Gene & Cell Therapy special event, where other registry observations in the same period cover different cancer and gene-therapy studies. That shared setting helps readers see this as part of a broader wave of new treatment development, while still keeping each study distinct.
The current record does not post results, and the primary completion date is estimated for 2039-03. For now, the key update is simply that a randomized Phase 3 study has been registered, with the latest known status still NOT_YET_RECRUITING. Readers watching this space can use the internal links to follow related registry observations in the same therapy area.